Kwang Joong Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Kwang Joong Kim has a total of 173 co-authors. Here are the top co-authors by number of shared publications:
Eun Joo Park
Department of Dermatology, College of Medicine, Hallym University, Anyang, Korea
37 shared publications- Eun Joo Park
Department of Dermatology, Hallym University Sacred Heart Hospital, Anyang, Korea
30 shared publications Eun Byul Cho
Department of Dermatology, Hallym University Sacred Heart Hospital, Anyang, Korea
18 shared publicationsKwang Joong Kim
From the Department of Dermatology, College of Medicine, Hallym University, Sacred Heart Hospital, Anyang-Si Gyeonggi-Do, South Korea
15 shared publications- Eun Byul Cho
Department of Dermatology, Hallym University Sacred Heart Hospital, Anyang, Korea
11 shared publications - Ye Ji Jang
Department of Dermatology, Hallym University Sacred Heart Hospital, Anyang, Korea
10 shared publications
Latest Publications
- 7 September 2026
- Published by Wiley in Lasers in Surgery and Medicine
Clinical Efficacy and Histologic Correlation of a High‐Powered 675‐nm Non‐Ablative Diode Laser for Facial Rejuvenation
Objectives: The 675‐nm diode laser has emerged as a novel wavelength for non‐ablative skin rejuvenation, with potential advantages in selective dermal targeting and minimal epidermal injury. However, integrated clinical and biologic evidence across multiple esthetic domains remains limited. This study aimed to evaluate the efficacy and safety of high‐powered 675‐nm laser treatment for facial rejuvenation in a real‐world clinical setting. Materials and Methods: In this prospective single‐center study, 22 adults with facial erythema, fine wrinkles, enlarged pores, and textural irregularities underwent 3 monthly sessions of 675‐nm non‐ablative diode laser treatment. Objective outcomes were assessed using three‐dimensional imaging at baseline and the 3‐month follow‐up (T3). Blinded Global Esthetic Improvement Scale (GAIS) evaluations were performed for pigmentation and erythema. An exploratory histologic analysis was conducted in a subset of participants. Results: Eighteen participants completed the paired imaging analysis. Significant improvements were observed in wrinkle (+0.73 ± 0.86, p = 0.002), pore (+1.54 ± 2.24, p = 0.010), and smoothness scores (+2.18 ± 2.35, p = 0.001), with large effect sizes (Cohen's d z 0.69–0.93). Blinded GAIS assessments demonstrated ≥ 50% improvement in 61.1% of participants for both pigmentation and erythema. Treatment‐related pain was mild (median visual analog scale score: 2.0), and no serious adverse events or post‐inflammatory hyperpigmentation were observed. Histologic findings suggested increased dermal collagen components. Conclusion: High‐powered 675‐nm non‐ablative diode laser treatment significantly improved objective skin texture parameters and provided clinically perceptible improvements in pigmentation and erythema, with favorable tolerability. These findings support its role as a versatile and effective modality for comprehensive facial rejuvenation.
- 7 September 2026
- Published by Wiley in Lasers in Surgery and Medicine
Clinical Efficacy and Histologic Correlation of a High‐Powered 675‐nm Non‐Ablative Diode Laser for Facial Rejuvenation
Objectives: The 675‐nm diode laser has emerged as a novel wavelength for non‐ablative skin rejuvenation, with potential advantages in selective dermal targeting and minimal epidermal injury. However, integrated clinical and biologic evidence across multiple esthetic domains remains limited. This study aimed to evaluate the efficacy and safety of high‐powered 675‐nm laser treatment for facial rejuvenation in a real‐world clinical setting. Materials and Methods: In this prospective single‐center study, 22 adults with facial erythema, fine wrinkles, enlarged pores, and textural irregularities underwent 3 monthly sessions of 675‐nm non‐ablative diode laser treatment. Objective outcomes were assessed using three‐dimensional imaging at baseline and the 3‐month follow‐up (T3). Blinded Global Esthetic Improvement Scale (GAIS) evaluations were performed for pigmentation and erythema. An exploratory histologic analysis was conducted in a subset of participants. Results: Eighteen participants completed the paired imaging analysis. Significant improvements were observed in wrinkle (+0.73 ± 0.86, p = 0.002), pore (+1.54 ± 2.24, p = 0.010), and smoothness scores (+2.18 ± 2.35, p = 0.001), with large effect sizes (Cohen's d z 0.69–0.93). Blinded GAIS assessments demonstrated ≥ 50% improvement in 61.1% of participants for both pigmentation and erythema. Treatment‐related pain was mild (median visual analog scale score: 2.0), and no serious adverse events or post‐inflammatory hyperpigmentation were observed. Histologic findings suggested increased dermal collagen components. Conclusion: High‐powered 675‐nm non‐ablative diode laser treatment significantly improved objective skin texture parameters and provided clinically perceptible improvements in pigmentation and erythema, with favorable tolerability. These findings support its role as a versatile and effective modality for comprehensive facial rejuvenation.
- 1 July 2026
- Published by Wiley in International Journal of Dermatology
- Vol. 65 (10) , 2005-2007
Clinicopathological Challenge: A Painful Violaceous Reticulated Patch
Hyaluronic acid (HA) injection is commonly used as a treatment for osteoarthritis for lubrication, and its therapeutic efficacy is gaining increasing importance in an aging society. Vascular complications are infrequent; existing literature typically describes knee involvement manifesting as retiform purpura patterns, managed with heparin or hyaluronidase. Herein, we present a case of livedo racemosa after intra‐articular (IA) HA injection which resolved with acetylsalicylic acid and topical fusidic acid with a conservative approach. To our knowledge, while antithrombotic and rheological strategies for IA HA complications predominantly involve low‐molecular‐weight heparin, pentoxifylline, or subcutaneous hyaluronidase, reports of successful resolution through the maintenance of acetylsalicylic acid monotherapy are limited.
- 1 July 2026
- Published by Wiley in International Journal of Dermatology
- Vol. 65 (10) , 2005-2007
Clinicopathological Challenge: A Painful Violaceous Reticulated Patch
Hyaluronic acid (HA) injection is commonly used as a treatment for osteoarthritis for lubrication, and its therapeutic efficacy is gaining increasing importance in an aging society. Vascular complications are infrequent; existing literature typically describes knee involvement manifesting as retiform purpura patterns, managed with heparin or hyaluronidase. Herein, we present a case of livedo racemosa after intra‐articular (IA) HA injection which resolved with acetylsalicylic acid and topical fusidic acid with a conservative approach. To our knowledge, while antithrombotic and rheological strategies for IA HA complications predominantly involve low‐molecular‐weight heparin, pentoxifylline, or subcutaneous hyaluronidase, reports of successful resolution through the maintenance of acetylsalicylic acid monotherapy are limited.
- Open Access
- 15 January 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (2) , 704
Factors Predicting Guselkumab Treatment Response in Patients with Moderate-to-Severe Plaque Psoriasis: A Post Hoc Analysis of Korean Real-World Data
Background: This study aimed to identify the baseline characteristics predictive of Psoriasis Area and Sensitivity Index (PASI) 90 response to guselkumab and assess treatment effectiveness outcomes for PASI 90 responders and PASI 90 non-responders. Methods: This post hoc analysis used data from a prospective, multicenter, observational study of guselkumab in Korean patients with moderate-to-severe psoriasis conducted between February 2019 and March 2022. Stepwise logistic regression analysis was used to identify baseline characteristics predictive of PASI 90 response. Results: Of 339 patients, 245 (72.3%) week-28 PASI 90 responders and 94 (27.7%) non-responders were identified. Baseline characteristics significantly predictive of PASI 90 response in multivariate logistic regression were absence of family history of psoriasis (odds ratio [OR]: 0.35; p = 0.0266), higher PASI score (OR: 1.22; p = 0.0006), higher body surface area of psoriasis involvement (OR: 0.95; p = 0.0127), prior phototherapy use (OR: 2.44; p = 0.0108), and reduced concomitant topical agent use (OR: 0.41; p = 0.0044). More PASI 90 responders versus non-responders achieved absolute PASI score ≤ 2 by week 44 (95.8% vs. 67.5%) and Dermatology Life Quality Index scores of 0 or 1 by week 28 (72.2% vs. 34.0%). Conclusions: Guselkumab PASI 90 responders had unique baseline characteristics that may predict positive treatment outcomes.
- 15 January 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (2) , 704
Open AccessFactors Predicting Guselkumab Treatment Response in Patients with Moderate-to-Severe Plaque Psoriasis: A Post Hoc Analysis of Korean Real-World Data
Background: This study aimed to identify the baseline characteristics predictive of Psoriasis Area and Sensitivity Index (PASI) 90 response to guselkumab and assess treatment effectiveness outcomes for PASI 90 responders and PASI 90 non-responders. Methods: This post hoc analysis used data from a prospective, multicenter, observational study of guselkumab in Korean patients with moderate-to-severe psoriasis conducted between February 2019 and March 2022. Stepwise logistic regression analysis was used to identify baseline characteristics predictive of PASI 90 response. Results: Of 339 patients, 245 (72.3%) week-28 PASI 90 responders and 94 (27.7%) non-responders were identified. Baseline characteristics significantly predictive of PASI 90 response in multivariate logistic regression were absence of family history of psoriasis (odds ratio [OR]: 0.35; p = 0.0266), higher PASI score (OR: 1.22; p = 0.0006), higher body surface area of psoriasis involvement (OR: 0.95; p = 0.0127), prior phototherapy use (OR: 2.44; p = 0.0108), and reduced concomitant topical agent use (OR: 0.41; p = 0.0044). More PASI 90 responders versus non-responders achieved absolute PASI score ≤ 2 by week 44 (95.8% vs. 67.5%) and Dermatology Life Quality Index scores of 0 or 1 by week 28 (72.2% vs. 34.0%). Conclusions: Guselkumab PASI 90 responders had unique baseline characteristics that may predict positive treatment outcomes.
- Open Access
- 30 June 2025
- Published by The Korean Society for Psoriasis in Journal of the Korean Society for Psoriasis
- Vol. 22 (1) , 39-41
Erectile dysfunction with secukinumab
Dayeon Jung, Ye Ji Jang, Eun Joo Park, Kwang Ho Kim, Kwang Joong Kim. Journal of the Korean Society for Psoriasis 2025;22:39-41. https://doi.org/10.23203/JKSP.2025.22.1.39
- 30 June 2025
- Published by The Korean Society for Psoriasis in Journal of the Korean Society for Psoriasis
- Vol. 22 (1) , 39-41
Open AccessErectile dysfunction with secukinumab
Dayeon Jung, Ye Ji Jang, Eun Joo Park, Kwang Ho Kim, Kwang Joong Kim. Journal of the Korean Society for Psoriasis 2025;22:39-41. https://doi.org/10.23203/JKSP.2025.22.1.39
- Open Access
- 1 January 2025
- Published by XMLink in Annals of Dermatology
- Vol. 37 (5) , 269-275
Botulinum Toxin A Modulates Keratinocyte Proliferation and Inflammatory and Pruritic Mediators in Wound Healing
Jung D, et al. Ann Dermatol. 2025 Jun;37:e24. https://doi.org/10.5021/ad.25.063
- 1 January 2025
- Published by XMLink in Annals of Dermatology
- Vol. 37 (5) , 269-275
Open AccessBotulinum Toxin A Modulates Keratinocyte Proliferation and Inflammatory and Pruritic Mediators in Wound Healing
Jung D, et al. Ann Dermatol. 2025 Jun;37:e24. https://doi.org/10.5021/ad.25.063
- Open Access
- 1 January 2025
- Published by Wiley in Dermatologic Therapy
- Vol. 2025 (1)
Alitretinoin for the Treatment of Lichen Amyloidosis: A Retrospective, Observational Study and an In Vitro Study
Background: Lichen amyloidosis (LA) is the most common form of localized cutaneous amyloidosis, often accompanied by severe pruritus. Treatment options are limited, and alitretinoin, a systemic retinoid, has shown promise in managing refractory cases. Objective: This study aimed to evaluate the efficacy of alitretinoin in treating LA and its effects on keratinocytes. Methods: We conducted a retrospective analysis of 13 patients diagnosed with LA treated with alitretinoin. In addition, an in vitro study assessed the impact of alitretinoin on keratinocyte inflammation markers. Results: Of the 13 patients, 4 (30.77%) achieved complete clearance of lesions, demonstrating excellent improvement. The remaining 9 (69.23%) showed substantial improvement, with almost clear or mild residual lesions. In vitro, alitretinoin significantly decreased levels of IL‐33, periostin, CCL5, and PTGES. Conclusion: Alitretinoin demonstrated effectiveness in treating LA, with favorable outcomes in both clinical and in vitro settings. These findings support alitretinoin as a viable treatment option for LA.
- 1 January 2025
- Published by Wiley in Dermatologic Therapy
- Vol. 2025 (1)
Open AccessAlitretinoin for the Treatment of Lichen Amyloidosis: A Retrospective, Observational Study and an In Vitro Study
Background: Lichen amyloidosis (LA) is the most common form of localized cutaneous amyloidosis, often accompanied by severe pruritus. Treatment options are limited, and alitretinoin, a systemic retinoid, has shown promise in managing refractory cases. Objective: This study aimed to evaluate the efficacy of alitretinoin in treating LA and its effects on keratinocytes. Methods: We conducted a retrospective analysis of 13 patients diagnosed with LA treated with alitretinoin. In addition, an in vitro study assessed the impact of alitretinoin on keratinocyte inflammation markers. Results: Of the 13 patients, 4 (30.77%) achieved complete clearance of lesions, demonstrating excellent improvement. The remaining 9 (69.23%) showed substantial improvement, with almost clear or mild residual lesions. In vitro, alitretinoin significantly decreased levels of IL‐33, periostin, CCL5, and PTGES. Conclusion: Alitretinoin demonstrated effectiveness in treating LA, with favorable outcomes in both clinical and in vitro settings. These findings support alitretinoin as a viable treatment option for LA.
- Open Access
- 1 January 2025
- Published by XMLink in Annals of Dermatology
- Vol. 37 (2) , 75-85
Primary Cutaneous CD30+ Lymphoproliferative Disorders in South Korea: A Nationwide, Multi-Center, Retrospective, Clinical, and Prognostic Study
Lee WJ, et al. Ann Dermatol. 2024 Dec;37:e1. https://doi.org/10.5021/ad.24.120
- 1 January 2025
- Published by XMLink in Annals of Dermatology
- Vol. 37 (2) , 75-85
Open AccessPrimary Cutaneous CD30+ Lymphoproliferative Disorders in South Korea: A Nationwide, Multi-Center, Retrospective, Clinical, and Prognostic Study
Lee WJ, et al. Ann Dermatol. 2024 Dec;37:e1. https://doi.org/10.5021/ad.24.120
- Open Access
- 31 December 2024
- Published by The Korean Society for Psoriasis in Journal of the Korean Society for Psoriasis
- Vol. 21 (2) , 90-92
New onset of guttate psoriasis after COVID-19 vaccine
Jin Hyeok Hyeong, Ye Ji Jang, Kwang Ho Kim, Kwang Joong Kim, Eun Joo Park. Journal of the Korean Society for Psoriasis 2024;21:90-2. https://doi.org/10.23203/JKSP.2024.21.2.90
- 31 December 2024
- Published by The Korean Society for Psoriasis in Journal of the Korean Society for Psoriasis
- Vol. 21 (2) , 90-92
Open AccessNew onset of guttate psoriasis after COVID-19 vaccine
Jin Hyeok Hyeong, Ye Ji Jang, Kwang Ho Kim, Kwang Joong Kim, Eun Joo Park. Journal of the Korean Society for Psoriasis 2024;21:90-2. https://doi.org/10.23203/JKSP.2024.21.2.90
- Open Access
- 1 September 2024
- Published by Medknow in Indian Journal of Dermatology
- Vol. 69 (5) , 416-418
Ixekizumab-Associated Generalized Vitiligo and Pruritus in a Psoriatic Patient
- 1 September 2024
- Published by Medknow in Indian Journal of Dermatology
- Vol. 69 (5) , 416-418
Open AccessIxekizumab-Associated Generalized Vitiligo and Pruritus in a Psoriatic Patient
- 17 April 2024
- Published by Wolters Kluwer Health in Dermatologic Surgery
- Vol. 50 (8) , 739-745
Facial Skin Rejuvenation Using Poly-dl-Lactic Acid Injected With a Laser-Generated Needle-Free Microjet Injector
BACKGROUND: A laser-induced needle-free microjet injector was developed for rapid, high-speed drug delivery of microliters into the skin. OBJECTIVE: This study evaluated the clinical rejuvenation effect of repeated dermal injections of the collagen simulator poly-dl-lactic acid (PDLA) using a laser-induced needle-free microjet injector. METHODS: Five PDLA injection sessions using a laser-induced needle-free microjet injector were conducted in patients concerned about aging skin. Facial uplifting, darkness, redness, roughness, pore size, subjective satisfaction, and side effects were evaluated before each session and 4 weeks after treatment completion. Histological evaluation was also performed with immunohistochemical staining of collagen and elastic fibers. RESULTS: The clinical results of 27 female patients were evaluated. The treatment resulted in a noticeable skin surface uplifting (0.711 ± 0.42 mm) and significant improvements in darkness (p = .013), redness (p = .009), and roughness (p = .036), with no significant difference in the pore size (p = .770). Patients were reported being satisfied with the overall therapeutic effects, despite mild and tolerable adverse effects. Histological findings revealed growth and thickening of collagen and elastic fibers, with marked increase in collagen I and III levels. CONCLUSION: Repeated dermal injections of PDLA using a laser-induced microjet injector offer excellent drug delivery, achieving high efficacy in skin rejuvenation, patient satisfaction, and safety.
- 17 April 2024
- Published by Wolters Kluwer Health in Dermatologic Surgery
- Vol. 50 (8) , 739-745
Facial Skin Rejuvenation Using Poly-dl-Lactic Acid Injected With a Laser-Generated Needle-Free Microjet Injector
BACKGROUND: A laser-induced needle-free microjet injector was developed for rapid, high-speed drug delivery of microliters into the skin. OBJECTIVE: This study evaluated the clinical rejuvenation effect of repeated dermal injections of the collagen simulator poly-dl-lactic acid (PDLA) using a laser-induced needle-free microjet injector. METHODS: Five PDLA injection sessions using a laser-induced needle-free microjet injector were conducted in patients concerned about aging skin. Facial uplifting, darkness, redness, roughness, pore size, subjective satisfaction, and side effects were evaluated before each session and 4 weeks after treatment completion. Histological evaluation was also performed with immunohistochemical staining of collagen and elastic fibers. RESULTS: The clinical results of 27 female patients were evaluated. The treatment resulted in a noticeable skin surface uplifting (0.711 ± 0.42 mm) and significant improvements in darkness (p = .013), redness (p = .009), and roughness (p = .036), with no significant difference in the pore size (p = .770). Patients were reported being satisfied with the overall therapeutic effects, despite mild and tolerable adverse effects. Histological findings revealed growth and thickening of collagen and elastic fibers, with marked increase in collagen I and III levels. CONCLUSION: Repeated dermal injections of PDLA using a laser-induced microjet injector offer excellent drug delivery, achieving high efficacy in skin rejuvenation, patient satisfaction, and safety.